ResearcherKunming Institute of ZoologyActive in the last 2 years
Xudong Zhao
Matched on ORCID iD 0000-0001-9126-7365; OpenAlex author ID A5011468720. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 5)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 10
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 6
- Corrigendum to "Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models" [Translational Oncology volume… Last author DOI 10.1016/j.tranon.2024.102252↗
- Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models. Last author DOI 10.1016/j.tranon.2023.101803↗
- GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer. Last author DOI 10.1186/s13045-023-01467-9↗
- Smad4 deficiency substitutes Cdkn2b but not Cdkn2a downregulation in pancreatic cancer following induction of genetic events in adult mice. Last author DOI 10.1016/j.pan.2021.01.004↗
- Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation. Co-author DOI 10.1038/s41388-018-0556-x↗
- CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A. Last author DOI 10.1038/onc.2017.316↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yuncang Yuan · 3 shared papers, 2023–2025 · strength 0.65
- Paper Corrigendum to "Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinica… DOI 10.1016/j.tranon.2024.102252↗
- Paper Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models. DOI 10.1016/j.tranon.2023.101803↗
- Paper GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer. DOI 10.1186/s13045-023-01467-9↗
- Yongjie Zhu · 2 shared papers, 2024–2025 · strength 0.47
- Paper Corrigendum to "Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinica… DOI 10.1016/j.tranon.2024.102252↗
- Paper Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models. DOI 10.1016/j.tranon.2023.101803↗
- Xu Wei Luo · 2 shared papers, 2024–2025 · strength 0.47
- Paper Corrigendum to "Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinica… DOI 10.1016/j.tranon.2024.102252↗
- Paper Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models. DOI 10.1016/j.tranon.2023.101803↗
- Bin Sun · 3 shared papers, 2018–2023 · strength 0.37
- Paper GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer. DOI 10.1186/s13045-023-01467-9↗
- Paper Smad4 deficiency substitutes Cdkn2b but not Cdkn2a downregulation in pancreatic cancer following induction of genetic e… DOI 10.1016/j.pan.2021.01.004↗
- Paper CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition… DOI 10.1038/onc.2017.316↗
- Qiu Tu · 3 shared papers, 2018–2021 · strength 0.29
- Paper Smad4 deficiency substitutes Cdkn2b but not Cdkn2a downregulation in pancreatic cancer following induction of genetic e… DOI 10.1016/j.pan.2021.01.004↗
- Paper Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation. DOI 10.1038/s41388-018-0556-x↗
- Paper CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition… DOI 10.1038/onc.2017.316↗
- Jiawei Fan · 1 shared paper, 2023 · strength 0.18
- Ren Lai · 2 shared papers, 2018–2019 · strength 0.16
- Xintong Jia · 1 shared paper, 2021 · strength 0.12
- Cheng Xu · 1 shared paper, 2019 · strength 0.09
- Dejun Yang · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.